{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T13:36:57Z","timestamp":1793799417226,"version":"4.6.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-026-01552-3","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T10:31:51Z","timestamp":1786703511000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Vaccinology in the twenty-first century revisited"],"prefix":"10.1038","volume":"11","author":[{"given":"Alan D. T.","family":"Barrett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Rupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard W.","family":"Titball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"von Messling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"1552_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/npjvaccines.2016.9","volume":"1","author":"A Barrett","year":"2016","unstructured":"Barrett, A. Vaccinology in the twenty-first century. npj Vaccines 1, 16009 (2016).","journal-title":"npj Vaccines"},{"key":"1552_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-0159-8","volume":"5","author":"NAC Jackson","year":"2020","unstructured":"Jackson, N. A. C. et al. The promise of mRNA vaccines: a biotech and industrial perspective. npj Vaccines 5, 11 (2020).","journal-title":"npj Vaccines"},{"key":"1552_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00503-y","volume":"7","author":"T Travieso","year":"2022","unstructured":"Travieso, T. et al. The use of viral vectors in vaccine development. npj Vaccines 7, 75 (2022).","journal-title":"npj Vaccines"},{"key":"1552_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00330-7","volume":"6","author":"B Nguyen","year":"2021","unstructured":"Nguyen, B. & Tolia, N. H. Protein-based antigen presentation platforms for nanoparticle vaccines. npj Vaccines 6, 70 (2021).","journal-title":"npj Vaccines"},{"key":"1552_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-019-0110-z","volume":"4","author":"E Kay","year":"2019","unstructured":"Kay, E., Cuccui, J. & Wren, B. W. Recent advances in the production of recombinant glycoconjugate vaccines. npj Vaccines 4, 16 (2019).","journal-title":"npj Vaccines"},{"key":"1552_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00751-6","volume":"8","author":"L Zhang","year":"2023","unstructured":"Zhang, L. et al. Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability. npj Vaccines 8, 156 (2023).","journal-title":"npj Vaccines"},{"key":"1552_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-0163-z","volume":"5","author":"AS Espeseth","year":"2020","unstructured":"Espeseth, A. S. et al. Modified mRNA\/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection. npj Vaccines 5, 16 (2020).","journal-title":"npj Vaccines"},{"key":"1552_CR8","unstructured":"Lipid nanoparticle (LNP)-adjuvanted vaccines https:\/\/www.nature.com\/collections\/ggjcbccdfc accessed 23 July 2026."},{"key":"1552_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-025-01258-y","volume":"10","author":"F Villanueva-Flores","year":"2025","unstructured":"Villanueva-Flores, F., Sanchez-Villamil, J. I. & Garcia-Atutxa, I. AI-driven epitope prediction: a systematic review, comparative analysis, and practical guide for vaccine development. npj Vaccines 10, 207 (2025).","journal-title":"npj Vaccines"},{"key":"1552_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00795-8","volume":"9","author":"B Bravi","year":"2024","unstructured":"Bravi, B. Development and use of machine learning algorithms in vaccine target selection. npj Vaccines 9, 15 (2024).","journal-title":"npj Vaccines"},{"key":"1552_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00418-0","volume":"6","author":"DT O\u2019Hagan","year":"2021","unstructured":"O\u2019Hagan, D. T. et al. \u201cWorld in motion\u201d \u2013 emulsion adjuvants rising to meet the pandemic challenges. npj Vaccines 6, 158 (2021).","journal-title":"npj Vaccines"},{"key":"1552_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00351-2","volume":"6","author":"M Borey","year":"2021","unstructured":"Borey, M. et al. Links between fecal microbiota and the response to vaccination against influenza A virus in pigs. npj Vaccines 6, 92 (2021).","journal-title":"npj Vaccines"},{"key":"1552_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00874-4","volume":"9","author":"Y Hou","year":"2024","unstructured":"Hou, Y. et al. Insights into vaccines for elderly individuals: from the impacts of immunosenescence to delivery strategies. npj Vaccines 9, 77 (2024).","journal-title":"npj Vaccines"},{"key":"1552_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-0196-3","volume":"5","author":"PE Duffy","year":"2020","unstructured":"Duffy, P. E. & Patrick Gorres, J. Malaria vaccines since 2000: progress, priorities, products. npj Vaccines 5, 48 (2020).","journal-title":"npj Vaccines"},{"key":"1552_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-0160-2","volume":"5","author":"A Blank","year":"2020","unstructured":"Blank, A. et al. Immunization with full-length Plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial. npj Vaccines 5, 10 (2020).","journal-title":"npj Vaccines"},{"key":"1552_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00527-4","volume":"7","author":"MF Gruber","year":"2022","unstructured":"Gruber, M. F. Current status of monkeypox vaccines. npj Vaccines 7, 94 (2022).","journal-title":"npj Vaccines"},{"key":"1552_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00658-2","volume":"8","author":"SJ Thomas","year":"2023","unstructured":"Thomas, S. J. Is new dengue vaccine efficacy data a relief or cause for concern? npj Vaccines 8, 55 (2023).","journal-title":"npj Vaccines"},{"key":"1552_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00985-y","volume":"9","author":"A Marzi","year":"2024","unstructured":"Marzi, A. & Feldmann, H. Filovirus vaccines as a response paradigm for emerging infectious diseases. npj Vaccines 9, 186 (2024).","journal-title":"npj Vaccines"},{"key":"1552_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-00261-9","volume":"5","author":"R Roozendaal","year":"2020","unstructured":"Roozendaal, R. et al. Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate. npj Vaccines 5, 112 (2020).","journal-title":"npj Vaccines"},{"key":"1552_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00734-7","volume":"8","author":"TJ Ruckwardt","year":"2023","unstructured":"Ruckwardt, T. J. The road to approved vaccines for respiratory syncytial virus. npj Vaccines 8, 138 (2023).","journal-title":"npj Vaccines"},{"key":"1552_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-0174-9","volume":"5","author":"O Pleguezuelos","year":"2020","unstructured":"Pleguezuelos, O. et al. Efficacy of FLU-v, a broad-spectrum influenza vaccine, in a randomized phase IIb human influenza challenge study. npj Vaccines 5, 22 (2020).","journal-title":"npj Vaccines"},{"key":"1552_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00376-7","volume":"6","author":"JH Lee","year":"2021","unstructured":"Lee, J. H. et al. Vaccine genetics of IGHV1-2 VRC01-class broadly neutralizing antibody precursor na\u00efve human B cells. npj Vaccines 6, 113 (2021).","journal-title":"npj Vaccines"},{"key":"1552_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00420-6","volume":"6","author":"S Chivukula","year":"2021","unstructured":"Chivukula, S. et al. Development of multivalent mRNA vaccine candidates for seasonal or pandemic influenza. npj Vaccines 6, 153 (2021).","journal-title":"npj Vaccines"},{"key":"1552_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00307-6","volume":"6","author":"KO Saunders","year":"2021","unstructured":"Saunders, K. O. et al. Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates. npj Vaccines 6, 50 (2021).","journal-title":"npj Vaccines"},{"key":"1552_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00845-9","volume":"9","author":"HLX Vu","year":"2024","unstructured":"Vu, H. L. X. & McVey, D. S. Recent progress on gene-deleted live-attenuated African swine fever virus vaccines. npj Vaccines 9, 60 (2024).","journal-title":"npj Vaccines"},{"key":"1552_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-025-01195-w","volume":"10","author":"W Li","year":"2025","unstructured":"Li, W. et al. Safety and efficacy of live attenuated PEDV vaccines for neonatal protection. npj Vaccines 10, 131 (2025).","journal-title":"npj Vaccines"},{"key":"1552_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-026-01414-y","volume":"11","author":"BL Bearson","year":"2026","unstructured":"Bearson, B. L. et al. Chicken vaccination reduces colonization and dissemination of Salmonella serovar Enteritidis with decreased susceptibility to ciprofloxacin. npj Vaccines 11, 88 (2026).","journal-title":"npj Vaccines"},{"key":"1552_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-025-01212-y","volume":"10","author":"RK McLean","year":"2025","unstructured":"McLean, R. K. et al. Nipah virus vaccines evaluated in pigs as a \u2018One Health\u2019 approach to protect public health. npj Vaccines 10, 163 (2025).","journal-title":"npj Vaccines"},{"key":"1552_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-0161-1","volume":"5","author":"AL St. John","year":"2020","unstructured":"St. John, A. L. et al. Novel mucosal adjuvant, mastoparan-7, improves cocaine vaccine efficacy. npj Vaccines 5, 12 (2020).","journal-title":"npj Vaccines"},{"key":"1552_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00329-0","volume":"6","author":"AE Stone","year":"2021","unstructured":"Stone, A. E. et al. Fentanyl conjugate vaccine by injected or mucosal delivery with dmLT or LTA1 adjuvants implicates IgA in protection from drug challenge. npj Vaccines 6, 69 (2021).","journal-title":"npj Vaccines"},{"key":"1552_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-025-01083-3","volume":"10","author":"A Angelidou","year":"2025","unstructured":"Angelidou, A. et al. Product and trial design considerations on the path towards a vaccine to combat opioid overdose. npj Vaccines 10, 35 (2025).","journal-title":"npj Vaccines"},{"key":"1552_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-018-0046-8","volume":"3","author":"A Bittar","year":"2018","unstructured":"Bittar, A., Sengupta, U. & Kayed, R. Prospects for strain-specific immunotherapy in Alzheimer\u2019s disease and tauopathies. npj Vaccines 3, 9 (2018).","journal-title":"npj Vaccines"},{"key":"1552_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-026-01379-y","volume":"11","author":"PA Vinot","year":"2026","unstructured":"Vinot, P. A. et al. Immune checkpoint-engineered virus-like particles induce antigen-specific immune tolerance and protect against food allergy. npj Vaccines 11, 43 (2026).","journal-title":"npj Vaccines"},{"key":"1552_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00535-4","volume":"7","author":"C Casper","year":"2022","unstructured":"Casper, C. et al. KSHV (HHV8) vaccine: promises and potential pitfalls for a new anti-cancer vaccine. npj Vaccines 7, 108 (2022).","journal-title":"npj Vaccines"},{"key":"1552_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-019-0103-y","volume":"4","author":"RE Hollingsworth","year":"2019","unstructured":"Hollingsworth, R. E. & Jansen, K. Turning the corner on therapeutic cancer vaccines. npj Vaccines 4, 7 (2019).","journal-title":"npj Vaccines"},{"key":"1552_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00813-3","volume":"9","author":"H Zhao","year":"2024","unstructured":"Zhao, H. et al. A therapeutic hepatitis B mRNA vaccine with strong immunogenicity and persistent virological suppression. npj Vaccines 9, 22 (2024).","journal-title":"npj Vaccines"},{"key":"1552_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00858-4","volume":"9","author":"F Bagnoli","year":"2024","unstructured":"Bagnoli, F. et al. Reverse development of vaccines against antimicrobial-resistant pathogens. npj Vaccines 9, 71 (2024).","journal-title":"npj Vaccines"},{"key":"1552_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00294-8","volume":"6","author":"LVN Oliveira","year":"2021","unstructured":"Oliveira, L. V. N. et al. Vaccines for human fungal diseases: close but still a long way to go. npj Vaccines 6, 33 (2021).","journal-title":"npj Vaccines"},{"key":"1552_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-019-0148-y","volume":"5","author":"P Bettencourt","year":"2020","unstructured":"Bettencourt, P. et al. Identification of antigens presented by MHC for vaccines against tuberculosis. npj Vaccines 5, 2 (2020).","journal-title":"npj Vaccines"},{"key":"1552_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00598-3","volume":"8","author":"O Teymournejad","year":"2023","unstructured":"Teymournejad, O. et al. Toxin expression during Staphylococcus aureus infection imprints host immunity to inhibit vaccine efficacy. npj Vaccines 8, 3 (2023).","journal-title":"npj Vaccines"},{"key":"1552_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00672-4","volume":"8","author":"X Wang","year":"2023","unstructured":"Wang, X. et al. Strong immune responses and protection of PcrV and OprF-I mRNA vaccine candidates against Pseudomonas aeruginosa. npj Vaccines 8, 76 (2023).","journal-title":"npj Vaccines"},{"key":"1552_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00668-0","volume":"8","author":"F Giannini","year":"2023","unstructured":"Giannini, F. et al. Modeling the potential health impact of prospective Strep A vaccines. npj Vaccines 8, 90 (2023).","journal-title":"npj Vaccines"},{"key":"1552_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00884-2","volume":"9","author":"KB Carlson","year":"2024","unstructured":"Carlson, K. B. et al. A narrative review of norovirus epidemiology, biology, and challenges to vaccine development. npj Vaccines 9, 94 (2024).","journal-title":"npj Vaccines"},{"key":"1552_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-019-0144-2","volume":"4","author":"E Petitdidier","year":"2019","unstructured":"Petitdidier, E. et al. Peptide-based vaccine successfully induces protective immunity against canine visceral leishmaniasis. npj Vaccines 4, 49 (2019).","journal-title":"npj Vaccines"},{"key":"1552_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-0188-3","volume":"5","author":"YC Kim","year":"2020","unstructured":"Kim, Y. C., Dema, B. & Reyes-Sandoval, A. COVID-19 vaccines: breaking record times to first-in-human trials. npj Vaccines 5, 34 (2020).","journal-title":"npj Vaccines"},{"key":"1552_CR46","unstructured":"WEBSITE WHO COVID (Immunization, Vaccines and Biologicals) https:\/\/www.who.int\/teams\/immunization-vaccines-and-biologicals\/diseases\/covid-19-(corona-virus) accessed 23 July (2026)."},{"key":"1552_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00292-w","volume":"6","author":"NC Kyriakidis","year":"2021","unstructured":"Kyriakidis, N. C. et al. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. npj Vaccines 6, 28 (2021).","journal-title":"npj Vaccines"},{"key":"1552_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00369-6","volume":"6","author":"FX Heinz","year":"2021","unstructured":"Heinz, F. X. & Stiasny, K. Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action. npj Vaccines 6, 104 (2021).","journal-title":"npj Vaccines"},{"key":"1552_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-00243-x","volume":"5","author":"R Bos","year":"2020","unstructured":"Bos, R. et al. Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses. npj Vaccines 5, 91 (2020).","journal-title":"npj Vaccines"},{"key":"1552_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00336-1","volume":"6","author":"I McDonald","year":"2021","unstructured":"McDonald, I. et al. Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2. npj Vaccines 6, 74 (2021).","journal-title":"npj Vaccines"},{"key":"1552_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-00221-3","volume":"5","author":"SP Graham","year":"2020","unstructured":"Graham, S. P. et al. Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19. npj Vaccines 5, 69 (2020).","journal-title":"npj Vaccines"},{"key":"1552_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00393-6","volume":"6","author":"H Kleanthous","year":"2021","unstructured":"Kleanthous, H. et al. Scientific rationale for developing potent RBD-based vaccines targeting COVID-19. npj Vaccines 6, 128 (2021).","journal-title":"npj Vaccines"},{"key":"1552_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00717-8","volume":"8","author":"C Singh","year":"2023","unstructured":"Singh, C. et al. Phase III Pivotal comparative clinical trial of intranasal (iNCOVACC) and intramuscular COVID-19 vaccine (Covaxin\u00ae). npj Vaccines 8, 125 (2023).","journal-title":"npj Vaccines"},{"key":"1552_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00323-6","volume":"6","author":"KP Acharya","year":"2021","unstructured":"Acharya, K. P., Ghimire, T. R. & Subramanya, S. H. Access to and equitable distribution of COVID-19 vaccine in low-income countries. npj Vaccines 6, 54 (2021).","journal-title":"npj Vaccines"},{"key":"1552_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00335-2","volume":"6","author":"S Kreps","year":"2021","unstructured":"Kreps, S. et al. Public attitudes toward COVID-19 vaccination: the role of vaccine attributes, incentives, and misinformation. npj Vaccines 6, 73 (2021).","journal-title":"npj Vaccines"},{"key":"1552_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00913-0","volume":"9","author":"I Casubhoy","year":"2024","unstructured":"Casubhoy, I. et al. A scoping review of global COVID-19 vaccine hesitancy among pregnant persons. npj Vaccines 9, 131 (2024).","journal-title":"npj Vaccines"},{"key":"1552_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00569-8","volume":"7","author":"A Buoninfante","year":"2022","unstructured":"Buoninfante, A. et al. Understanding thrombosis with thrombocytopenia syndrome after COVID-19 vaccination. npj Vaccines 7, 141 (2022).","journal-title":"npj Vaccines"},{"key":"1552_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-00249-5","volume":"5","author":"S Simpson","year":"2020","unstructured":"Simpson, S. et al. Navigating facilitated regulatory pathways during a disease X pandemic. npj Vaccines 5, 101 (2020).","journal-title":"npj Vaccines"},{"key":"1552_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00617-x","volume":"8","author":"C Milne","year":"2023","unstructured":"Milne, C. et al. Independent control of COVID-19 vaccines by EU Official Control Authority Batch Release: challenges, strengths and successes. npj Vaccines 8, 22 (2023).","journal-title":"npj Vaccines"},{"key":"1552_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00872-6","volume":"9","author":"DF King","year":"2024","unstructured":"King, D. F. et al. Realising the potential of correlates of protection for vaccine development, licensure and use: short summary. npj Vaccines 9, 82 (2024).","journal-title":"npj Vaccines"},{"key":"1552_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-0207-4","volume":"5","author":"RL Charlebois","year":"2020","unstructured":"Charlebois, R. L. et al. Sensitivity and breadth of detection of high-throughput sequencing for adventitious virus detection. npj Vaccines 5, 61 (2020).","journal-title":"npj Vaccines"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01552-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01552-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01552-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T10:31:53Z","timestamp":1786703513000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01552-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1552"],"URL":"https:\/\/doi.org\/10.1038\/s41541-026-01552-3","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"assertion":[{"value":"13 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.D.T.B. is Editor-in-Chief and R.E.R., R.W.T., and V.v.M. are Deputy Editors for\n                      npj Vaccines\n                      .","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"166"}}